| |

Comparing 3 Standard Treatments for Mesothelioma

ByHolly Zink

Comparing Three Frontline Treatments for Mesothelioma

There are three standard treatments for malignant pleural mesothelioma. Patients and doctors want to know which is more effective.

A new study from the Davidoff Cancer Center in Israel sought to do just that. This study compared three clinical trials of the standard treatments recommended for malignant mesothelioma. All three treatments involved different chemotherapy drugs.

Treatment A was cisplatin plus pemetrexed vs cisplatin. Treatment B was cisplatin plus pemetrexed plus bevacizumab vs cisplatin plus pemetrexed. And Treatment C was nivolumab plus ipilimumab vs cisplatin plus pemetrexed.

Urgent Need to Identify Effective Treatment Strategies

Malignant pleural mesothelioma is the primary cancer of the pleural lining. It is caused by exposure to asbestos. It affected more than 30,000 patients globally in 2020.

The prognosis is usually poor. Patient survival is approximately 12 months from diagnosis. Current standard treatments have only modestly improved patient survival.

There is an urgent need to identify new and effective treatment strategies. Since 2003, three different treatment strategies have been tested via clinical trials. These three treatment strategies are considered “frontline” therapies.

Each new treatment was designed to replace the previous therapy because of presumed better performance.

First, chemotherapy with two drugs: cisplatin and pemetrexed. It was replaced by chemotherapy with three drugs: cisplatin and pemetrexed plus the antiangiogenic bevacizumab. The third one was nivolumab plus ipilimumab. This latest strategy was recently approved by the US Food and Drug Administration.

There is a limited increase in survival benefits for each of these standard treatments. A new study performed a deeper analysis of the clinical trial designs and outcomes of these three treatments. Their goal was to understand how they truly benefit patients with malignant pleural mesothelioma.

Cost-Effectiveness Ratios for Approved Therapies

The comparison showed no superiority of Treatment C over Treatment B. But, all three clinical trials needed more patients to draw stronger conclusions.

The cost-effectiveness ratio of approved standard treatments is also debated. The estimated drug cost for cisplatin plus pemetrexed is $46,225 for 6 cycles. The cost for nivolumab plus ipilimumab is approximately $153,800 for 4 cycles. This shows the need to consider the best treatment options with greater care.

These high-cost cancer drugs are currently being appraised by national health agencies.

A recent analysis recommended 10 drugs for coverage by the national health system. But all 10 drugs included a financial agreement to improve cost-effectiveness. And seven were subject to more evidence for efficacy.

The present study showed that more clinical trial evidence was needed for clinical decision-making policies.

First Comparative Effectiveness Study for Mesothelioma Treatments

This is the first comparative effectiveness study on the three clinical trials and showed that the results of these clinical trials are not as clear as we hoped. More research is needed for the frontline treatments. Only then can doctors assess its real impact before it is approved for patients.

Source

Meirson, Tomer, Francesca Pentimalli, Francesco Cerza, Giovanni Baglio, Steven G. Gray, Pierpaolo Correale, Marija Krstic-Demonacos et al. “Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma.” JAMA Network Open 5, no. 3 (2022): e221490-e221490. http://jamanetwork.com/article.aspx?doi=10.1001/jamanetworkopen.2022.1490

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Chemical in Wine May Improve Mesothelioma Treatment

    ByAlex Strauss

    There’s new evidence that a compound found in red wine may help improve the effectiveness of chemotherapy treatment for malignant pleural mesothelioma. Last year, a team of Korean researchers released the world’s first study on the mesothelioma-fighting power of resveratrol, a natural phenol derived from the skin of red grapes and found in red wine and grape juice. Now, the same team says resveratrol also appears to enhance the chemosensitivity of malignant mesothelioma cells. Study author Yoon-Jin Lee and colleagues discovered  a synergistic cancer-fighting effect in mesothelioma cells treated with both resveratrol and clofarabine, a prescription drug often used to treat acute lymphoblastic leukemia. Together, resveratrol and clofarabine “induced a strong cytotoxic effect” by influencing levels of the tumor suppressor,…